First American Trust FSB Has $1.12 Million Holdings in Zoetis Inc. (NYSE:ZTS)

First American Trust FSB trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,862 shares of the company’s stock after selling 822 shares during the period. First American Trust FSB’s holdings in Zoetis were worth $1,118,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ZTS. Raymond James Financial Inc. acquired a new position in shares of Zoetis during the fourth quarter worth about $196,651,000. Polen Capital Management LLC raised its position in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after buying an additional 1,116,541 shares during the last quarter. Amundi lifted its stake in Zoetis by 46.2% in the 4th quarter. Amundi now owns 2,748,719 shares of the company’s stock valued at $453,355,000 after acquiring an additional 867,993 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock worth $144,917,000 after acquiring an additional 665,331 shares during the last quarter. Finally, Nordea Investment Management AB grew its stake in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on ZTS shares. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $163.22 on Tuesday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The firm has a market capitalization of $73.09 billion, a price-to-earnings ratio of 29.84, a P/E/G ratio of 2.78 and a beta of 0.94. The stock’s 50 day moving average price is $166.70 and its two-hundred day moving average price is $175.22. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.